Skip to main content

Risk-Adjusted Performance Measures: A Comment on Elbasha

A Letter to the Editor to this article was published on 17 June 2022

A Letter to the Editor to this article was published on 17 June 2022

The Original Article was published on 09 February 2022

This is a preview of subscription content, access via your institution.

References

  1. Elbasha E. Cost-effectiveness risk-aversion curves: comparison of risk-adjusted performance measures and expected-utility approaches. Pharmacoeconomics. 2022;40:497–507. https://doi.org/10.1007/s40273-021-01123-5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sendi P. Dealing with bad risk in cost-effectiveness analysis: the cost-effectiveness risk-aversion curve. Pharmacoeconomics. 2021;39:161–9.

    Article  Google Scholar 

  3. Sendi P, Matter-Walstra K, Schwenkglenks M. Handling uncertainty in cost-effectiveness analysis: budget impact and risk aversion. Healthcare. 2021;9:1419. https://doi.org/10.1007/s40273-020-00969-5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Plantinga A, van der Meer R, Sortino F. The impact of downside risk on risk-adjusted performace of mutual funds in the Euronext markets. (July 19, 2001), Available at https://doi.org/10.2139/ssrn.277352.

  5. Jia J, Dyer JS. A standard measure of risk and risk-value models. Manage Sci. 1996;42(12):1691–705.

    Article  Google Scholar 

  6. Sortino F, van der Meer R, Plantinga A. The dutch triangle: a framework to measure upside potential relative to downside risk. J Portf Manag. 1999;26(1):50–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pedram Sendi.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest; this commentary received no funding.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sendi, P., Schwenkglenks, M. Risk-Adjusted Performance Measures: A Comment on Elbasha. PharmacoEconomics 40, 739–740 (2022). https://doi.org/10.1007/s40273-022-01153-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-022-01153-7